Monoamine oxidase A and B substrates: Probing the pathway for drug development

Future Medicinal Chemistry

Volumn 6, Issue 6, 2014, Pages 697-717

  Chajkowski Scarry, Sarah ^a   Rimoldi, John M ^b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; FLUORESCENT DYE; IMINE; MONOAMINE OXIDASE INHIBITOR; AMINE OXIDASE (FLAVIN CONTAINING);

BIOCATALYST; DRUG DEVELOPMENT; ELECTRON TRANSPORT; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME STRUCTURE; ENZYME SUBSTRATE; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; MOLECULAR PROBE; NONHUMAN; NUCLEOPHILICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; X RAY ANALYSIS; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION;

ANIMALS; DRUG DISCOVERY; ENZYME ASSAYS; HUMANS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; POSITRON-EMISSION TOMOGRAPHY; SIGNAL TRANSDUCTION;

EID: 84902117557     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.23     Document Type: Review

References (138)

1. Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm. 118(7), 979-986 (2011).
2. Beaupre BA, Carmichael BR, Hoag MR, Shah DD, Moran GR. Renalase is an α-NAD(P)H oxidase/anomerase. J. Am. Chem. Soc. 135(37), 13980-13987 (2013).
3. Lienhart WD, Gudipati V, Macheroux P. The human flavoproteome. Arch. Biochem. Biophys. 535(2), 150-162 (2013).
4. Newton-Vinson P, Hubalek F, Edmondson DE. High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr. Purif. 20(2), 334-345 (2000).
5. Wang J, Edmondson DE. 2H kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme. Biochemistry 50(35), 7710-7717 (2011).
6. Arslan BK, Edmondson DE. Expression of zebrafish (Danio rerio) monoamine oxidase (MAO) in Pichia pastoris: purification and comparison with human MAO A and MAO B. Protein Expr. Purif. 70(2), 290-297 (2010).
7. Binda C, Mattevi A, Edmondson DE. Structural properties of human monoamine oxidases A and B. In: Monoamine Oxidase and their Inhibitors. Youdim MBH, Douce P (Eds). Academic Press, NY, USA, 1-11 (2011).
8. Ferino G, Vilar S, Matos MJ, Uriarte E, Cadoni E. Monoamine oxidase inhibitors: ten years of docking studies. Curr. Top. Med. Chem. 12(20), 2145-2162 (2012).
9. Novaroli L, Reist M, Favre E, Carotti A, Catto M, Carrupt P-A. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening. Bioorg. Med. Chem. 13(22), 6212-6217 (2005).
10. Edmondson DE, Binda C, Wang J, Upadhyay AK, Mattevi A. Molecular and mechanistic properties of the membranebound mitochondrial monoamine oxidases. Biochemistry 48(20), 4220-4230 (2009).
11. Li M, Binda C, Mattevi A, Edmondson DE. Functional role of the 'aromatic cage' in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. Biochemistry. 45(15), 4775-4784 (2006).
12. Borštnar R, Repic M, Kamerlin SCL, Vianello R, Mavri J. Computational study of the pKa values of potential catalytic residues in the active site of monoamine oxidase B. J. Chem. Theory Comput. 8(10), 3864-3870 (2012).
13. Edmondson DE, Binda C, Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch. Biochem. Biophys. 464(2), 269-276 (2007).
14. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE,Mattevi A.Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 9(1), 22-26 (2002).
15. Binda C, Li M, Hubalek F, Restelli N, Edmondson DE, Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. Proc. Natl Acad. Sci. USA 100(17), 9750-9755 (2003).
16. Milczek EM, Binda C, Rovida S, Mattevi A, Edmondson DE. The 'gating' residues Ile199 and Tyr326 in human monoamine oxidase B function in substrate and inhibitor recognition. FEBS J. 278(24), 4860-4869 (2011).
17. Bonivento D, Milczek EM, McDonald GR et al. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J. Biol. Chem. 285(47), 36849-36856 (2010).
18. McDonald GR, Olivieri A, Ramsay RR, Holt A. On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B. Pharmacol. Res. 62(6), 475-488 (2010).
19. Son S-Y, Ma J, Kondou Y, Yoshimura M, Yamashita E, Tsukihara T. Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors. Proc. Natl Acad. Sci. USA 105(15), 5739-5744 (2008).
20. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc. Natl Acad. Sci. USA 102(36), 12684-12689 (2005).
21. Upadhyay AK, Edmondson DE. Development of spinlabeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B. Biochemistry 48(18), 3928-3935 (2009).
22. Wang J, Edmondson DE. Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Biochemistry 50(13), 2499-2505 (2011).
23. Upadhyay AK, Wang J, Edmondson DE. Comparison of the structural properties of the active site cavities of human and rat monoamine oxidase A and B in their soluble and membranebound forms. Biochemistry 47(2), 526-536 (2008).
24. Novaroli L, Daina A, Favre E et al. Impact of speciesdependent differences on screening, design, and development of MAO B inhibitors. J. Med. Chem. 49(21), 6264-6272 (2006).
25. Sallinen V, Sundvik M, Reenila I et al. Hyperserotonergic phenotype after monoamine oxidase inhibition in larval zebrafish. J. Neurochem. 109(2), 403-415 (2009).
26. Aldeco M, Arslan BK, Edmondson DE. Catalytic and inhibitor binding properties of zebrafish monoamine oxidase (zMAO): comparisons with human MAO A and MAO B. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 159(2), 78-83 (2011).
27. Fierro A, Montecinos A, Gomez-Molina C et al. Similarities between the binding sites of monoamine oxidase (MAO) from different species-is zebrafish a useful model for the discovery of novel MAO inhibitors In: An Integrated View of the Molecular Recognition and Toxinology-From Analytical Procedures to Biomedical Applications. Baptista GR (Ed.). InTech, Rijeka, Croatia (2013).
28. Tipton KF, Davey GP, McDonald AG. Kinetic behavior and reversible inhibition of monoamine oxidases-enzymes that many want dead Int. Rev. Neurobiol. 100, 43-64 (2011)
29. Testa B, Pedretti A, Vistoli G. Reactions and enzymes in the metabolism of drugs and other xenobiotics. Drug Discov. Today 17(11-12), 549-560 (2012).
30. Strolin Benedetti M. FAD-dependent enzymes involved in the metabolic oxidation of xenobiotics. Ann. Pharm. Fr. 69(1), 45-52 (2011).
31. Kalgutkar AS, Stepan AF. Metabolic stability and analoguebased drug discovery. In: Analogue-Based Drug Discovery III. Wiley-VCH Verlag GmbH and Co. KGaA, Weinheim, Germany, 37-75 (2012).
32. Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab. Dispos. 33, 262-270 (2005).
33. Kamel A, Colizza K, Gunduz M, Harriman S, Obach RS. In vitro-in vivo correlation for intrinsic clearance for CP-409,092 and sumatriptan: a case study to predict the in vivo clearance for compounds metabolized by monoamine oxidase. Xenobiotica 42(4), 355-362 (2012).
34. Chiba K, Trevor A, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120(2), 574-578 (1984).
35. Carta AR, Carboni E, Spiga S. The MPTP/probenecid model of progressive parkinson's disease. In: Dopamine: Methods and Protocols. Kabbani N (Ed.). Humana Press, NY, USA, 295-308 (2013).
36. Kalgutkar AS, Dalvie DK, Castagnoli, N Jr., Taylor TJ. Interactions of Nitrogen-Containing Xenobiotics with Monoamine Oxidase (MAO) Isozymes A and B: SAR Studies on MAO Substrates and Inhibitors. Chem. Res. Toxicol. 14(9), 1139-1162 (2001).
37. Masic LP. Role of cyclic tertiary amine bioactivation to reactive iminium species: structure-toxicity relationship. Curr. Drug Metab. 12(1), 35-50 (2011).
38. Rimoldi JM, Puppali SG, Isin E, Bissel P, Khalil A, Castagnoli N Jr. A novel and selective monoamine oxidase B substrate. Bioorg. Med. Chem. 13(20), 5808-5813 (2005).
39. Bissel P, Khalil A, Rimoldi JM et al. Stereochemical studies on the novel monoamine oxidase B substrates (1R,6S)-and (1S,6R)-3-methyl-6-phenyl-3-aza- bicyclo[4.1.0]heptane. Bioorg. Med. Chem. 16(7), 3557-3564 (2008).
40. Pretorius A, Ogunrombi MO, Fourie H et al. Interactions of 1-methyl-3-phenylpyrrolidine and 3-methyl-1-phenyl-3-azabicyclo[3.1.0]hexane with monoamine oxidase B. Bioorg. Med. Chem. 18(11), 4111-4118 (2010).
41. Erickson DA, Hollfelder S, Tenge J, Gohdes M, Burkhardt JJ, Krieter PA. In vitro metabolism of the analgesic bicifadine in the mouse, rat, monkey, and human. Drug Metab. Dispos. 35(12), 2232-2241 (2007).
42. Musick TJ, Gohdes M, Duffy A, Erickson DA, Krieter PA. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey. Drug Metab. Dispos. 36(2), 241-251 (2008).
43. Krieter PA, Gohdes M, Musick TJ, Duncanson FP, Bridson WE. Pharmacokinetics, disposition, and metabolism of bicifadine in humans. Drug Metab. Dispos. 36(2), 252-259 (2008).
44. Micheli F, Cavanni P, Andreotti D et al. 6-(3,4-dichlorophenyl)-1- [(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor. J. Med. Chem. 53(13), 4989-5001 (2010).
45. Prins J, Westphal KG, Korte-Bouws GA et al. The potential and limitations of {DOV} 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats. Pharmacol. Biochem. Behav. 97(3), 444-452 (2011).
46. Orru R, Aldeco M, Edmondson DE. Do MAO A and MAO B utilize the same mechanism for the C-H bond cleavage step in catalysis Evidence suggesting differing mechanisms. J. Neural Transm. 120(6), 847-851 (2013).
47. Fitzpatrick PF. Oxidation of amines by flavoproteins. Arch. Biochem. Biophys. 493(1), 13-25 (2010).
48. Gaweska H, Fitzpatrick PF. Structures and mechanism of the monoamine oxidase family. Biomol. Concepts 2(5), 365-377 (2011).
49. Ramsay RR. Monoamine Oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery. Curr. Top. Med. Chem. 12(20), 2189-2209 (2012).
50. Silverman RB. Radical ideas about monoamine oxidase. Accounts Chem. Res. 28(8), 335-342 (1995).
51. Erdem SS, Buyukmeneke B. Computational investigation on the structure-activity relationship of the biradical mechanism for monoamine oxidase. J. Neural Transm. 118(7), 1021-1029 (2011).
52. Grimm ML, Allen WJ, Finn M,Tanko JM. Reaction of benzophenone triplet with aliphatic amines. What a potent neurotoxin can tell us about the reaction mechanism. Bioorg. Med. Chem. 19(4), 1458-1463 (2011).
53. Khan MN, Suzuki T, Miyata N. An overview of phenylcyclopropylamine derivatives: biochemical and biological significance and recent developments. Med. Res. Rev. 33(4), 873-910 (2013).
54. Binda C, Valente S, Romanenghi M et al. Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2. J. Am. Chem. Soc. 132(19), 6827-6833 (2010).
55. MacMillar S, Edmondson DE, Matsson O. Nitrogen kinetic isotope effects for the monoamine oxidase B-catalyzed oxidation of benzylamine and (1, 1-2H2)benzylamine: nitrogen rehybridization and CH bond cleavage are not concerted. J. Am. Chem. Soc. 133(32), 12319-12321 (2011).
56. Kachalova G, Decker K, Holt A, Bartunik HD. Crystallographic snapshots of the complete reaction cycle of nicotine degradation by an amine oxidase of the monoamine oxidase (MAO) family. Proc. Natl Acad. Sci. USA 108(12), 4800-4805 (2011).
57. Vianello R, Repi M, Mavri J. How are biogenic amines metabolized by monoamine oxidases Eur. J. Org. Chem. 2012(36), 7057-7065 (2012).
58. Akyuz MA, Erdem SS. Computational modeling of the direct hydride transfer mechanism for the MAO catalyzed oxidation of phenethylamine and benzylamine: ONIOM (QM/QM) calculations. J. Neural Transm. 120(6), 937-945 (2013).
59. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27(10), 789-797 (2013).
60. Lohle M, Storch A. Effects of monoamine oxidase type B inhibitors on motor and non-motor symptoms in Parkinson's disease: a systematic comparison of rasagiline and selegiline. Basal Ganglia. 2(Suppl. 4), S33-S40 (2012).
61. Teo KC, Ho S-L. Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson's disease. Transl. Neurodegener. 2(1), 19 (2013).
62. Kaludercic N, Carpi A, Menabo R, Lisa FD, Paolocci N. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim. Biophys. Acta 1813(7), 1323-1332 (2011).
63. Machado-Vieira R, Mallinger AG. Abnormal function of monoamine oxidase-A in comorbid major depressive disorder and cardiovascular disease: pathophysiological and therapeutic implications (review). Mol. Med. Reports. 6(5), 915-922 (2012).
64. Deftereos SN, Dodou E, Andronis C, Persidis A. From depression to neurodegeneration and heart failure: reexamining the potential of MAO inhibitors. Expert Rev. Clin. Pharmacol. 5(4), 413-425 (2012).
65. Flamand V, Zhao H, Peehl DM. Targeting monoamine oxidase A in advanced prostate cancer. J. Cancer Res. Clin. Oncol. 136(11), 1761-1771 (2010).
66. Lee HT, Choi MR, Doh MS, Jung KH, Chai YG. Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells. Oncol. Rep. 30(4), 1587-1592 (2013).
67. Carradori S, Secci D, Bolasco A, Chimenti P, D'Ascenzio M. Patent-related survey on new monoamine oxidase inhibitors and their therapeutic potential. Expert Opin. Ther. Pat. 22(7), 759-801 (2012).
68. Reis J, Encarnacao I, Gasper A, Morales A, Milhazes N, Borges F. Parkinson's disease management. Part II-discovery of MAO-B inhibitors based on nitrogen heterocycles and analogues. Curr. Top. Med. Chem. 12(20), 2116-2130 (2012).
69. Secci D, Carradori S, Bolasco A, Bizzarri B, D'Ascenzio M, Maccioni E. Discovery and optimization of pyrazoline derivatives as promising monoamine oxidase inhibitors. Curr. Top. Med. Chem. 12(20), 2240-2257 (2012).
70. Helguera AM, Perez-Machado G, Cordeiro MN, Borges F. Discovery of MAO-B inhibitors-present status and future directions part i: oxygen heterocycles and analogs. Mini Rev. Med. Chem. 12(10), 907-919 (2012).
71. Patil PO, Bari SB, Firke SD, Deshmukh PK, Donda ST, Patil DA. A comprehensive review on synthesis and designing aspects of coumarin derivatives as monoamine oxidase inhibitors for depression and Alzheimer's disease. Bioorg. Med. Chem. 21(9), 2434-2450 (2013).
72. Binda C, Hubalek F, Li M et al. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J. Med. Chem. 48(26), 8148-8154 (2005).
73. Borštnar R, Repi M, Kržan M, Mavri J, Vianello R. Irreversible inhibition of monoamine oxidase B by the antiparkinsonian medicines rasagiline and selegiline: a computational study. Eur. J. Org. Chem. 2011(32), 6419-6433 (2011).
74. Pavlin M, Mavri J, Repi M, Vianello R. Quantum-chemical approach to determining the high potency of clorgyline as an irreversible acetylenic monoamine oxidase inhibitor. J. Neural Transm. 120(6), 875-882 (2013).
75. Gaines KD, Hinson VK. Adjunctive therapy in Parkinson's disease: the role of rasagiline. Neuropsychiatr. Dis. Treat. 8, 285-294 (2012).
76. Song MS, Matveychuk D, MacKenzie EM, Duchcherer M, Mousseau DD, Baker GB. An update on amine oxidase inhibitors: Multifaceted drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 44,118-124 (2013).
77. Weinreb O, Amit T, Bar-Am O, Youdim MBH. Rasagiline: a novel anti-parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog. Neurobiol. 92(3), 330-344 (2010).
78. Naoi M, Maruyama W, Yi H. Rasagiline prevents apoptosis induced by PK11195, a ligand of the outer membrane translocator protein (18 kDa), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J. Neural Transm. 120(11), 1539-1551 (2013).
79. Barac YD, Bar-Am O, Liani E et al. I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the Senantiomer of rasagiline. PLoS ONE 7(11), e47890 (2012).
80. Bolea I, Gella A, Unzeta M. Propargylamine-derived multitarget-directed ligands: fighting Alzheimer's disease with monoamine oxidase inhibitors. J. Neural Transm. 120(6), 893-902 (2013).
81. Geldenhuys WJ, Youdim MBH, Carroll RT, Van der Schyf CJ. The emergence of designed multiple ligands for neurodegenerative disorders. Prog. Neurobiol. 94(4), 347-359 (2011).
82. Geldenhuys WJ, Van der Schyf CJ. Rationally designed multi-targeted agents against neurodegenerative diseases. Curr. Med. Chem. 20(13), 1662-1672 (2013).
83. Youdim MBH. Multi target neuroprotective and neurorestorative anti-parkinson and anti-alzheimer drugs ladostigil and M30 derived from rasagiline. Exp Neurobiol. 22(1), 1-10 (2013).
84. Bolea I, Juarez-Jimenez J, de los Ros C et al. Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl- 1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease. J. Med. Chem. 54(24), 8251-8270 (2011).
85. Weinreb O, Amit T, Bar-Am O, Youdim MBH. Ladostigil: a novel multimodal neuroprotective drug with cholinesterase and brain-selective monoamine oxidase inhibitory activities for Alzheimers disease treatment. Curr. Drug Targets. 13(4), 483-494 (2012).
86. Weinreb O, Amit T, Mandel S, Kupershmidt L, Youdim MBH. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxidants Redox Signal. 13(6), 919-949 (2010).
87. Zheng H, Youdim MBH, Fridkin M. Site-activated chelators targeting acetylcholinesterase and monoamine oxidase for Alzheimer's therapy. ACS Chem. Biol. 5(6), 603-610 (2010).
88. Zheng H, Youdim MBH, Fridkin M. Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities. ACS Chem. Neurosci. 1(11), 737-746 (2010).
89. Lu YY, Wang YG, Dai B et al. A novel fluorogenic probe for monoamine oxidase assays. Chin. Chem. Lett. 19(8), 947-950 (2008).
90. Valley MP, Zhou W, Hawkins EM et al. A bioluminescent assay for monoamine oxidase activity. Anal. Biochem. 359(2), 238-246 (2006).
91. Albers AE, Rawls KA, Chang CJ. Activity-based fluorescent reporters for monoamine oxidases in living cells. Chem Commun. 44, 4647-4649 (2007).
92. Chen G, Yee DJ, Gubernator NG, Sames D. Design of optical switches as metabolic indicators: new fluorogenic probes for monoamine oxidases (MAO A and B). J. Am. Chem. Soc. 127(13), 4544-4545 (2005).
93. Long S, Chen L, Xiang Y, Song M, Zheng Y, Zhu Q. An activity-based fluorogenic probe for sensitive and selective monoamine oxidase-B detection. Chem Commun. 48(57), 7164-7166 (2012).
94. Xiang Y, He B, Li X, Zhu Q. The design and synthesis of novel "turn-on" fluorescent probes to visualize monoamine oxidase-B in living cells. RSC Adv. 3(15), 4876-4879 (2013).
95. Shen W, Long S, Yu S, Chen W, Zhu Q. Design, synthesis, and evaluation of an activity-based probe for cellular imaging of monoamine oxidases. Med. Chem. Res. 21(11), 3858-3862 (2012).
96. Aw J, Shao Q, Yang Y, Jiang T, Ang C, Xing B. Synthesis and characterization of 2-(2′-hydroxy-5′-chlorophenyl)-6-chloro-4(3 H)-quinazolinone-based fluorogenic probes for cellular imaging of monoamine oxidases. Chem. Asian J. 5(6), 1317-1321 (2010).
97. Zhang Y, Xu Y, Tan S, Xu L, Qian X. Rapid and sensitive fluorescent probes for monoamine oxidases B to A at low concentrations. Tetrahedron Lett. 53(51), 6881-6884 (2012).
98. Kim D, Sambasivan S, Nam H et al. Reaction-based twophoton probes for in vitro analysis and cellular imaging of monoamine oxidase activity. Chem. Commun. 48(54), 6833-6835 (2012).
99. Peng L, Zhang G, Zhang D, Wang Y, Zhu D. A direct continuous fluorometric turn-on assay for monoamine oxidase B and its inhibitor-screening based on the abnormal fluorescent behavior of silole. Analyst 135(7), 1779-1784 (2010).
100. Yamaguchi K, Ueki R, Nonaka H, Sugihara F, Matsuda T, Sando S. Design of chemical shift-switching 19F magnetic resonance imaging probe for specific detection of human monoamine oxidase A. J. Am. Chem. Soc. 133(36), 14208-14211 (2011).
101. Krysiak JM, Kreuzer J, Macheroux P, Hermetter A, Sieber SA, Breinbauer R. Activity-based probes for studying the activity of flavin-dependent oxidases and for the protein target profiling of monoamine oxidase inhibitors. Angew. Chem. Int. Ed. 51(28), 7035-7040 (2012).
102. Ueki R, Yamaguchi K, Nonaka H, Sando S. 1H NMR probe for in situ monitoring of dopamine metabolism and its application to inhibitor screening. J. Am. Chem. Soc. 134(30), 12398-12401 (2012).
103. Fowler JS, Logan J, Volkow ND, Wang G-J, MacGregor RR, Ding Y-S. Monoamine oxidase: radiotracer development and human studies. Methods 27(3), 263-277 (2002).
104. Kersemans K, Van Laeken N, De Vos F. Radiochemistry devoted to the production of monoamine oxidase (MAO-A and MAO-B) ligands for brain imaging with positron emission tomography. J. Label. Compd. Radiopharm. 56(3-4), 78-88 (2013).
105. Fowler JS, Logan J, Volkow ND, Wang GJ. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol. Imaging Biol. 7(6), 377-387 (2005).
106. Logan J, Fowler JS, Ding Y-S,Strategy for the formation of parametric images under conditions of low injected radioactivity applied to PET studies with the irreversible monoamine oxidase A tracers [11C]clorgyline and deuteriumsubstituted [11C]clorgyline. J. Cereb. Blood Flow Metab. 22,1367-1376 (2002).
107. Fowler JS, Ding Y-S, Logan J et al. Species differences in [11C]clorgyline binding in brain. Nucl. Med. Biol. 28(7), 779-785 (2001).
108. Di Santo R, Costi R, Roux A et al. Design, synthesis, and biological activities of pyrrolylethanoneamine derivatives, a novel class of monoamine oxidases inhibitors. J. Med. Chem. 48(13), 4220-4223 (2005).
109. Jensen SB, Olsen AK, Pedersen K, Cumming P. Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [11C]harmine and [11C]raclopride. Synapse 59(7), 427-434 (2006).
110. De Bruyne S, La Regina G, Staelens S et al. Radiosynthesis and in vivo evaluation of [11C]-labelled pyrrole-2-carboxamide derivates as novel radioligands for PET imaging of monoamine oxidase A. Nucl. Med. Biol. 37(4), 459-467 (2010).
111. Bottlaender M, Valette H, Delforge J et al. In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [11C]befloxatone and the multi-injection approach. J. Cereb. Blood Flow Metab. 30, 792-800 (2010).
112. Hosten B, Boisgard R, Jacob A et al. [11C]befloxatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: a PET study using Bcrp TGEM knockout rats. Eur. J. Pharm. Sci. 50(3-4), 520-525 (2013).
113. Bergstrom M, Westerberg G, Langstrom B. 11C-harmine as a tracer for monoamine oxidase a (MAO-A): in vitro and in vivo studies. Nucl. Med. Biol. 24(4), 287-293 (1997).
114. Bergstrom M, Westerberg G, Nemeth G et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur. J. Clin. Pharmacol. 52(2), 121-128 (1997).
115. Bottlaender M, Dolle F, Guenther I et al. Mapping the cerebral monoamine oxidase type A: Positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone. J. Pharmacol. Exp. Ther. 305(2), 467-473 (2003).
116. Dolle F, Valette H, Bramoulle Y et al. Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A. Bioorg. Med. Chem. Lett. 13(10), 1771-1775 (2003).
117. Sacher J, Rabiner EA, Clark M et al. Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [11C]-harmine positron emission tomography study. J. Cereb. Blood Flow Metab. 32(3), 443-446 (2012).
118. Fowler JS, MacGregor RR, Wolf AP et al. Mapping human brain monoamine oxidase A and B with carbon-11-labeled suicide inactivators and PET. Science 235(4787), 481-485 (1987).
119. Carter SF, Scholl M, Almkvist O et al. Evidence for astrocytosis in prodromal alzheimer disease provided by 11C-deuterium-l-deprenyl: a multitracer PET paradigm combining-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J. Nucl. Med. 53, 37-46 (2012).
120. Freedman NMT, Mishani E, Krausz Y et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using 11C-l-deprenyl and PET-deprenyl and PET. J. Nucl. Med. 46(10), 1618-1624 (2005).
121. Fowler JS, Wang G-J, Logan J et al. Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-l-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J. Nucl. Med. 36, 1255-1262 (1995).
122. Johansson A, Engler H, Blomquist G et al. Evidence for astrocytosis in ALS demonstrated by [11C](l)-deprenyl-D2 PET. J. Neurol. Sci. 255(1-2), 17-22 (2007).
123. Hirvonen J, Kailajarvi M, Haltia T et al. Assessment of MAO-B occupancy in the brain with PET and [11C]-ldeprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin. Pharmacol. Ther. 85(5), 506-512 (2009).
124. Nag S, Kettschau G, Heinrich T et al. Synthesis and biological evaluation of novel propargyl amines as potential fluorine-18 labeled radioligands for detection of MAO-B activity. Bioorg. Med. Chem. 21(1), 186-195 (2013).
125. Nag S, Lehmann L, Heinrich T et al. Synthesis of three novel fluorine-18 labeled analogues of l-deprenyl for positron emission tomography (PET) studies of Monoamine oxidase B (MAO-B)-deprenyl for positron emission tomography (PET) studies of Monoamine oxidase B (MAO-B). J. Med. Chem. 54(20), 7023-7029 (2011).
126. Nag S, Lehmann L, Kettschau G et al. Synthesis and evaluation of [18F]fluororasagiline, a novel positron emission tomography (PET) radioligand for monoamine oxidase B (MAO-B). Bioorg. Med. Chem. 20(9), 3065-3071 (2012).
127. Nag S, Lehmann L, Kettschau G et al. Development of a novel fluorine-18 labeled deuterated fluororasagiline ([18F] fluororasagiline-D2) radioligand for {PET} studies of monoamino oxidase B (MAO-B). Bioorg. Med. Chem. 21 (6634-6641(2013).
128. Vasdev N, Sadovski O, Moran MD et al. Development of new radiopharmaceuticals for imaging monoamine oxidase B. Nucl. Med. Biol. 38(7), 933-943 (2011).
129. Bramoulle Y, Puech F, Saba W et al. Radiosynthesis of (S)-5-methoxymethyl-3-[6-(4,4,4-trifluorobutoxy)benzo[d] isoxazol-3-yl] oxazolidin-2-[11C]one ([11C]SL25.1188), novel radioligand for imaging monoamine oxidase-B with PET. J. Label. Compd. Radiopharm. 51(3) 153-158 (2008).
130. Saba W, Valette H, Peyronneau M-A et al. [11C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse64(1), 61-69 (2010).
131. Vasdev N, Sadovski O, Garcia A et al. Radiosynthesis of [11C] SL25.1188 via [11C]CO2 fixation for imaging monoamine oxidase B. J. Label. Compd. Radiopharm. 54(10), 678-680 (2011).
132. Tong J, Meyer J, Furukawa Y et al. Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J. Cereb. Blood Flow Metab. 33(6), 863-871 (2013).
133. Turner NJ. Enantioselective oxidation of C-O and C-N bonds using oxidases. Chem. Rev. 111(7), 4073-4087 (2011).
134. Atkin KE, Reiss R, Koehler V et al. The structure of monoamine oxidase from Aspergillus niger provides a molecular context for improvements in activity obtained by directed evolution. J. Mol. Biol. 384(5), 1218-1231 (2008).
135. Znabet A, Ruijter E, de Kanter FJJ et al. Highly stereoselective synthesis of substituted prolyl peptides using a combination of biocatalytic desymmetrization and multicomponent reactions. Angew. Chem. Int. Ed. 49(31), 5289-5292 (2010).
136. Li T, Liang J, Ambrogelly A et al. Efficient, chemoenzymatic process for manufacture of the boceprevir bicyclic [3.1.0] proline intermediate based on amine oxidase-catalyzed desymmetrization. J. Am. Chem. Soc. 134(14), 6467-6472 (2012).
137. Rowles I, Malone KJ, Etchells LL, Willies SC, Turner NJ. Directed evolution of the enzyme monoamine oxidase (MAO-N): highly efficient chemo-enzymatic deracemisation of the alkaloid crispine A. ChemCatChem 4(9), 1259-1261 (2012).
138. Ghislieri D, Green AP, Pontini M et al. Engineering an enantioselective amine oxidase for the synthesis of pharmaceutical building blocks and alkaloid natural products. J. Am. Chem. Soc. 135(29), 10863-10869 (2013).